Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Executive Summary
Merck is assuring analysts that its massive commercial restructuring continues to benefit, not stifle, product growth, as company executives reported lower-than-expected sales and earnings April 21
You may also be interested in...
Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug
Meanwhile, the drug maker hopes to file a different drug, talcagepant, to treat acute migraines, but has yet to say when that will happen.
Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug
Meanwhile, the drug maker hopes to file a different drug, talcagepant, to treat acute migraines, but has yet to say when that will happen.
Merck/Schering Merger Brings A Partial Solution For Sales & Marketing
When Merck and Schering Plough executives promoted their proposed $41 billion merger March 9, they forecasted compounded annual earnings growth in the high single digits over each of the next several years. But they paid scant attention to top-line growth